Comparative Pharmacology
Head-to-head clinical analysis: ACETIC ACID W HYDROCORTISONE versus ZYLET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACETIC ACID W HYDROCORTISONE versus ZYLET.
ACETIC ACID W/ HYDROCORTISONE vs ZYLET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetic acid exerts antibacterial and antifungal activity by lowering pH and disrupting microbial cell membranes. Hydrocortisone is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Loteprednol etabonate is a corticosteroid that inhibits phospholipase A2 activity, reducing prostaglandin and leukotriene synthesis. Tobramycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis.
1 applicatorful (approximately 5 g) of the cream or ointment (containing 2% acetic acid and 1% hydrocortisone) inserted intravaginally once or twice daily for 7 days.
One to two drops into the conjunctival sac of the affected eye(s) every 4 to 6 hours. In severe cases, every 1 to 2 hours for the first 24 to 48 hours.
None Documented
None Documented
Acetic acid: not applicable; hydrocortisone: plasma half-life ~1.5 hours (biologic half-life 8–12 hours). Due to low systemic absorption from topical application, systemic half-life is clinically irrelevant.
ZYLET: not applicable (fixed-dose combination); Loteprednol: 2-3 hours; Tobramycin: 2-3 hours. Clinical context: no accumulation with qid dosing.
Acetic acid: minimal systemic absorption; hydrocortisone: hepatic metabolism, renal excretion of metabolites (<5% unchanged). Less than 10% of applied dose excreted in urine as metabolites; biliary/fecal excretion negligible.
Renal (30% unchanged), biliary/fecal (70% as metabolites)
Category D/X
Category C
Corticosteroid
Corticosteroid/Antibiotic Combination (Ophthalmic)